New combo aims to tackle Hard-to-Treat breast cancer

NCT ID NCT07446452

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a combination of two drugs—disitamab vedotin and bevacizumab—in 37 people with HER2-low metastatic breast cancer whose disease progressed after prior T-DXd therapy. The goal is to see if the combo can shrink tumors and delay progression. Researchers will also study side effects and look for biomarkers that predict who benefits most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: disitamab vedotin (a targeted drug) combined with bevacizumab (an anti-angiogenesis drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with HER2-low breast cancer whose disease has worsened after prior therapy.
What could go wrong: This is a small, early-phase trial (37 people) with no control group, so results may not be definitive. Side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-LOW BREAST CANCER

Contacts and locations

Locations

The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.